JOP20240210A1 - مثبطات kras - Google Patents
مثبطات krasInfo
- Publication number
- JOP20240210A1 JOP20240210A1 JOJO/P/2024/0210A JOP20240210A JOP20240210A1 JO P20240210 A1 JOP20240210 A1 JO P20240210A1 JO P20240210 A JOP20240210 A JO P20240210A JO P20240210 A1 JOP20240210 A1 JO P20240210A1
- Authority
- JO
- Jordan
- Prior art keywords
- kras inhibitors
- pharmaceutically acceptable
- acceptable salts
- kras
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323607P | 2022-03-25 | 2022-03-25 | |
| US202263406906P | 2022-09-15 | 2022-09-15 | |
| US202263386404P | 2022-12-07 | 2022-12-07 | |
| PCT/US2023/016257 WO2023183585A1 (en) | 2022-03-25 | 2023-03-24 | Kras inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240210A1 true JOP20240210A1 (ar) | 2024-09-26 |
Family
ID=86331239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0210A JOP20240210A1 (ar) | 2022-03-25 | 2024-09-26 | مثبطات kras |
Country Status (16)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| KR20250164300A (ko) * | 2023-03-30 | 2025-11-24 | 일라이 릴리 앤드 캄파니 | KRas 억제제 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| US20240368193A1 (en) * | 2023-03-31 | 2024-11-07 | Eli Lilly And Company | Kras inhibitors |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025038936A1 (en) | 2023-08-17 | 2025-02-20 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202535880A (zh) * | 2023-10-30 | 2025-09-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合雜芳基類化合物、其製備方法及其在醫藥上的應用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547457A (zh) * | 2024-04-08 | 2025-12-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 二氫呋喃并[3,4-f]喹唑啉類化合物、其製備方法及其在醫藥上的應用 |
| WO2025214344A1 (zh) * | 2024-04-09 | 2025-10-16 | 上海和誉生物医药科技有限公司 | 一种kras抑制剂及其在药学上的应用 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026059955A1 (en) * | 2024-09-11 | 2026-03-19 | Eli Lilly And Company | (3-((6-(2-amino-benzo[d]thiazol-4-yl)-3-(pyrrolidin-1-yl)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)amino)- piperidin-2-one derivatives as kras inhibitors for the treatment of cancer |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026075942A1 (en) * | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Kras inhibitors |
| WO2026075945A1 (en) | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Kras inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3030582A1 (en) | 2015-07-22 | 2017-01-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Compounds and uses thereof in the treatment of cancers and other medical conditions |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| TW202033518A (zh) * | 2018-10-15 | 2020-09-16 | 美商美國禮來大藥廠 | Kras g12c 抑制劑 |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| PT3886991T (pt) | 2019-12-11 | 2022-10-17 | Lilly Co Eli | Inibidores de kras g12c |
| WO2021244603A1 (en) * | 2020-06-04 | 2021-12-09 | Shanghai Antengene Corporation Limited | Inhibitors of kras g12c protein and uses thereof |
| CN113880827B (zh) | 2020-07-03 | 2024-10-01 | 苏州闻天医药科技有限公司 | 一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途 |
| CA3191279A1 (en) | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| US20240166660A1 (en) | 2021-01-15 | 2024-05-23 | Beigene Switzerland Gmbh | Kras g12c inhibitors |
| WO2022184178A1 (en) | 2021-03-05 | 2022-09-09 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| JP2024510207A (ja) * | 2021-03-12 | 2024-03-06 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤 |
| WO2022261154A1 (en) * | 2021-06-09 | 2022-12-15 | Eli Lilly And Company | Substituted fused azines as kras g12d inhibitors |
| WO2023061294A1 (zh) | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
-
2023
- 2023-03-24 MX MX2024011631A patent/MX2024011631A/es unknown
- 2023-03-24 AU AU2023241055A patent/AU2023241055A1/en active Pending
- 2023-03-24 EP EP23723097.4A patent/EP4499233A1/en active Pending
- 2023-03-24 KR KR1020257020079A patent/KR20250093430A/ko active Pending
- 2023-03-24 IL IL315782A patent/IL315782A/en unknown
- 2023-03-24 PE PE2024001867A patent/PE20251071A1/es unknown
- 2023-03-24 KR KR1020247035268A patent/KR102847563B1/ko active Active
- 2023-03-24 WO PCT/US2023/016257 patent/WO2023183585A1/en not_active Ceased
- 2023-03-24 US US18/189,713 patent/US12351591B2/en active Active
- 2023-03-24 CN CN202380030401.9A patent/CN119095853A/zh active Pending
- 2023-03-24 JP JP2024556680A patent/JP7676677B2/ja active Active
- 2023-03-24 CA CA3246810A patent/CA3246810A1/en active Pending
- 2023-03-25 TW TW113108193A patent/TW202438502A/zh unknown
- 2023-03-25 TW TW112111395A patent/TWI852436B/zh active
-
2024
- 2024-09-17 CO CONC2024/0012604A patent/CO2024012604A2/es unknown
- 2024-09-20 DO DO2024000186A patent/DOP2024000186A/es unknown
- 2024-09-25 CL CL2024002874A patent/CL2024002874A1/es unknown
- 2024-09-26 JO JOJO/P/2024/0210A patent/JOP20240210A1/ar unknown
-
2025
- 2025-04-30 JP JP2025075148A patent/JP2025118729A/ja active Pending
- 2025-05-29 US US19/222,746 patent/US20250289830A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2024000186A (es) | 2024-10-31 |
| KR20250093430A (ko) | 2025-06-24 |
| IL315782A (en) | 2024-11-01 |
| CO2024012604A2 (es) | 2024-12-09 |
| KR102847563B1 (ko) | 2025-08-20 |
| KR20240160650A (ko) | 2024-11-11 |
| US20240043451A1 (en) | 2024-02-08 |
| US12351591B2 (en) | 2025-07-08 |
| PE20251071A1 (es) | 2025-04-10 |
| TWI852436B (zh) | 2024-08-11 |
| CN119095853A (zh) | 2024-12-06 |
| MX2024011631A (es) | 2024-09-30 |
| CL2024002874A1 (es) | 2024-12-20 |
| JP2025118729A (ja) | 2025-08-13 |
| AU2023241055A1 (en) | 2024-10-10 |
| JP2025512811A (ja) | 2025-04-22 |
| US20250289830A1 (en) | 2025-09-18 |
| CA3246810A1 (en) | 2023-09-28 |
| TW202404572A (zh) | 2024-02-01 |
| WO2023183585A1 (en) | 2023-09-28 |
| TW202438502A (zh) | 2024-10-01 |
| JP7676677B2 (ja) | 2025-05-14 |
| EP4499233A1 (en) | 2025-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20240210A1 (ar) | مثبطات kras | |
| JOP20250246A1 (ar) | مثبطات kras | |
| JOP20240216A1 (ar) | مثبطات kras g12c | |
| MX2025011447A (es) | Inhibidores de kras | |
| ZA202309638B (en) | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof | |
| AU2019310335A8 (en) | Methods of treating cancer with PI3K inhibitor, GDC-0077 | |
| JOP20240237A1 (ar) | مركبات أريل غير متجانسة لمعالجة الألم | |
| CL2023001367A1 (es) | Inhibidores de btk | |
| MX2024005107A (es) | Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer. | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| BR112023007912A2 (pt) | Formas cristalinas de um composto inibidor de kras g12c | |
| ZA202212095B (en) | Il4i1 inhibitors and methods of use | |
| MX2023005806A (es) | Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). | |
| MA69153A1 (fr) | Méthodes de traitement d'une splénomégalie | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| MX2023011441A (es) | Uso de inhibidores de pi3k-delta para el tratamiento de cancer pancreatico. | |
| MX2025005021A (es) | Inhibidores de cromanona alostericos de fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| WO2021262562A3 (en) | Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof | |
| MX2024010802A (es) | Combinaciones farmaceuticas para uso en el tratamiento de enfermedades neoplasicas. | |
| MX2024010607A (es) | Terapia combinada de un inhibidor de pi3k y un inhibidor de pd-1 | |
| CY1125521T1 (el) | Παραγωγα 2-οξο-θειαζολιου ως α2α αναστολεις και ενωσεις για χρηση στη θεραπεια καρκινου | |
| GEAP202516658A (en) | Ripk1 inhibitors and methods of use | |
| JOP20180089B1 (ar) | طرق علاج سرطانات الأطفال |